Shorter Long-term Post-transplant Life Expectancy May Be Due to Prior Chemotherapy for the Underlying Disease: Analysis of 3012 Patients with Acute Myeloid Leukemia Enrolled on 9 Consecutive ECOG-ACRIN Trials

Overview

Journal Bone Marrow Transplant

Specialty General Surgery

Date 2024 May 22

PMID 38778148

Authors

C Ganzel

Y Wang

K Roopcharan

Z Sun

J M Rowe

H F Fernandez

E M Paietta

S M Luger

H M Lazarus

L D Cripe

D Douer

P H Wiernik

M S Tallman

M R Litzow

Affiliations

Soon will be listed here.

Abstract

Several studies reported that patients with acute myeloid leukemia (AML) who remain in long-term remission after allogeneic or autologous transplant have a shorter life expectancy, compared to the general population. However, little is known about the life expectancy of adult long-term survivors of AML who were treated with chemotherapy alone without a transplant and there have been no comparisons with survival among the general population. The current study indicates that the life expectancy of AML patients who achieved and maintained CR for at least 3 years is shorter than expected for age in the US population. This was observed also in patients who did not undergo a transplant including those who have not relapsed during the entire long follow-up period. Thus, late relapse does not explain why patients without transplants have a shortened life expectancy. Taken together, these data strongly suggest that prior chemotherapy for the underlying AML is at least a major contributing factor for the known shortened life expectancy post-transplant.

References

Watts J, Wang X, Litzow M, Luger S, Lazarus H, Cassileth P . Younger adults with acute myeloid leukemia in remission for ≥ 3 years have a high likelihood of cure: The ECOG experience in over 1200 patients. Leuk Res. 2014; 38(8):901-6. PMC: 4326112. DOI: 10.1016/j.leukres.2014.05.018. View

Molgaard-Hansen L, Mottonen M, Glosli H, Jonmundsson G, Abrahamsson J, Hasle H . Treatment-related deaths in second complete remission in childhood acute myeloid leukaemia. Br J Haematol. 2011; 152(5):623-30. DOI: 10.1111/j.1365-2141.2010.08554.x. View

Bhatia S, Francisco L, Carter A, Sun C, Baker K, Gurney J . Late mortality after allogeneic hematopoietic cell transplantation and functional status of long-term survivors: report from the Bone Marrow Transplant Survivor Study. Blood. 2007; 110(10):3784-92. PMC: 2077324. DOI: 10.1182/blood-2007-03-082933. View

Cassileth P, Lee S, Litzow M, Miller K, Stadtmauer E, Tallman M . Intensified induction chemotherapy in adult acute myeloid leukemia followed by high-dose chemotherapy and autologous peripheral blood stem cell transplantation: an Eastern Cooperative Oncology Group trial (E4995). Leuk Lymphoma. 2004; 46(1):55-61. DOI: 10.1080/10428190412331283288. View

Wingard J, Majhail N, Brazauskas R, Wang Z, Sobocinski K, Jacobsohn D . Long-term survival and late deaths after allogeneic hematopoietic cell transplantation. J Clin Oncol. 2011; 29(16):2230-9. PMC: 3107742. DOI: 10.1200/JCO.2010.33.7212. View

Major C, Kantarjian H, Sasaki K, Borthakur G, Kadia T, Pemmaraju N . Survivorship in AML - a landmark analysis on the outcomes of acute myelogenous leukemia patients after maintaining complete remission for at least 3 years. Leuk Lymphoma. 2020; 61(13):3120-3127. PMC: 11537313. DOI: 10.1080/10428194.2020.1802450. View

Pond G, Lipton J, Messner H . Long-term survival after blood and marrow transplantation: comparison with an age- and gender-matched normative population. Biol Blood Marrow Transplant. 2006; 12(4):422-9. DOI: 10.1016/j.bbmt.2005.11.518. View

Socie G, Stone J, Wingard J, Weisdorf D, Henslee-Downey P, Bredeson C . Long-term survival and late deaths after allogeneic bone marrow transplantation. Late Effects Working Committee of the International Bone Marrow Transplant Registry. N Engl J Med. 1999; 341(1):14-21. DOI: 10.1056/NEJM199907013410103. View

Czerw T, Labopin M, Gorin N, Giebel S, Blaise D, Meloni G . Long-term follow-up of patients with acute myeloid leukemia surviving and free of disease recurrence for at least 2 years after autologous stem cell transplantation: A report from the Acute Leukemia Working Party of the European Society for Blood.... Cancer. 2016; 122(12):1880-7. DOI: 10.1002/cncr.29990. View

10.

Cassileth P, Harrington D, Appelbaum F, Lazarus H, Rowe J, Paietta E . Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission. N Engl J Med. 1998; 339(23):1649-56. DOI: 10.1056/NEJM199812033392301. View

11.

Cripe L, Rader K, Tallman M, Gordon M, Paietta E, Bennett J . Phase II trial of subcutaneous recombinant human interleukin 11 with subcutaneous recombinant human granulocyte-macrophage colony stimulating factor in patients with acute myeloid leukemia (AML) receiving high-dose cytarabine during induction: ECOG.... Leuk Res. 2006; 30(7):823-7. DOI: 10.1016/j.leukres.2005.11.006. View

12.

Yeh J, Ward Z, Chaudhry A, Liu Q, Yasui Y, Armstrong G . Life Expectancy of Adult Survivors of Childhood Cancer Over 3 Decades. JAMA Oncol. 2020; 6(3):350-357. PMC: 6990848. DOI: 10.1001/jamaoncol.2019.5582. View

13.

Cassileth P, Andersen J, Lazarus H, COLVIN O, Bennett J, Stadtmauer E . Autologous bone marrow transplant in acute myeloid leukemia in first remission. J Clin Oncol. 1993; 11(2):314-9. DOI: 10.1200/JCO.1993.11.2.314. View

14.

Jaiswal S, Natarajan P, Silver A, Gibson C, Bick A, Shvartz E . Clonal Hematopoiesis and Risk of Atherosclerotic Cardiovascular Disease. N Engl J Med. 2017; 377(2):111-121. PMC: 6717509. DOI: 10.1056/NEJMoa1701719. View

15.

Bhattacharya R, Zekavat S, Haessler J, Fornage M, Raffield L, Uddin M . Clonal Hematopoiesis Is Associated With Higher Risk of Stroke. Stroke. 2021; 53(3):788-797. PMC: 8885769. DOI: 10.1161/STROKEAHA.121.037388. View

16.

Martin P, Counts Jr G, Appelbaum F, Lee S, Sanders J, Deeg H . Life expectancy in patients surviving more than 5 years after hematopoietic cell transplantation. J Clin Oncol. 2010; 28(6):1011-6. PMC: 2834427. DOI: 10.1200/JCO.2009.25.6693. View

17.

Rowe J, Neuberg D, Friedenberg W, Bennett J, Paietta E, Makary A . A phase 3 study of three induction regimens and of priming with GM-CSF in older adults with acute myeloid leukemia: a trial by the Eastern Cooperative Oncology Group. Blood. 2003; 103(2):479-85. DOI: 10.1182/blood-2003-05-1686. View

18.

El-Cheikh J, Bidaoui G, Saleh M, Moukalled N, Abou Dalle I, Bazarbachi A . Venetoclax: A New Partner in the Novel Treatment Era for Acute Myeloid Leukemia and Myelodysplastic Syndrome. Clin Hematol Int. 2023; 5(2-3):143-154. PMC: 10241752. DOI: 10.1007/s44228-023-00041-x. View

19.

Thomas E . Does bone marrow transplantation confer a normal life span?. N Engl J Med. 1999; 341(1):50-1. DOI: 10.1056/NEJM199907013410110. View

20.

Cripe L, Uno H, Paietta E, Litzow M, Ketterling R, Bennett J . Zosuquidar, a novel modulator of P-glycoprotein, does not improve the outcome of older patients with newly diagnosed acute myeloid leukemia: a randomized, placebo-controlled trial of the Eastern Cooperative Oncology Group 3999. Blood. 2010; 116(20):4077-85. PMC: 2993615. DOI: 10.1182/blood-2010-04-277269. View